RFPL4 Inhibitors
Chemical inhibitors of RFPL4 function through various molecular mechanisms to modulate its activity within cellular processes. 1,10-Phenanthroline, for example, operates by chelating metal ions that are vital for the catalytic activity of metalloenzymes. This chelation can inhibit the enzymatic activity of RFPL4 if it relies on such metal co-factors. In a similar vein, Triptolide affects the function of RFPL4 by inhibiting several transcription factors and disrupting the NF-κB pathway, which may regulate pathways that RFPL4 is involved in. PD98059 and U0126 specifically target the MAPK/ERK signaling pathway, inhibiting MEK1/2 and consequently reducing the activity of downstream pathways that could involve RFPL4. This results in a diminished activation and overall functionality of RFPL4.
Further inhibitors like LY294002 and Wortmannin exert their effects through the inhibition of PI3K, which plays a crucial role in the PI3K/Akt pathway, a regulator of a myriad of cellular processes including some that RFPL4 may participate in. Rapamycin, by inhibiting mTOR, a central kinase within the same pathway, can also lead to a decrease in RFPL4 activity by dampening the pathway's activity. SB203580 and SP600125 inhibit p38 MAP kinase and JNK, respectively, both of which are part of the MAPK signaling pathway. The inhibition of these kinases can lead to reduced activity of pathways crucial for RFPL4's function. ZM-447439, which inhibits Aurora kinase, and Roscovitine, which targets cyclin-dependent kinases (CDKs), can also reduce RFPL4 activity by interfering with cell cycle regulation or mitotic processes. Thapsigargin, by inhibiting the SERCA pump, induces elevated cytosolic calcium levels, which can alter multiple signaling pathways, including those regulated by RFPL4, thus inhibiting its function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
1,10-Phenanthroline | 66-71-7 | sc-255888 sc-255888A | 2.5 g 5 g | $23.00 $31.00 | ||
1,10-Phenanthroline can chelate metal ions required for the catalytic activity of metalloenzymes. If RFPL4 requires metal co-factors for its function, the chelation of these ions would lead to inhibition of RFPL4's enzymatic activity. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Triptolide inhibits the activity of several transcription factors and can affect the NF-κB pathway. Given that RFPL4 is involved in pathways that could be regulated by NF-κB, triptolide's inhibition of this pathway can result in the functional inhibition of RFPL4. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which is upstream of MAPK/ERK signaling. Since RFPL4 is involved in pathways that are regulated by MAPK/ERK signaling, inhibition by PD98059 can lead to decreased activation of this pathway, thus inhibiting RFPL4 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, which is part of the PI3K/Akt pathway, a known regulator of many cellular processes including those that RFPL4 may be involved in. Inhibition of PI3K thus can lead to functional inhibition of RFPL4. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a key kinase in the PI3K/Akt pathway, which could be crucial for RFPL4 function. Inhibition of mTOR by rapamycin can lead to a decrease in RFPL4 activity by reducing the pathway's overall activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. Since the p38 MAP kinase pathway regulates numerous cellular functions which RFPL4 might be involved in, inhibition of this kinase can lead to functional inhibition of RFPL4. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK signaling pathway. By inhibiting JNK, SP600125 could reduce the activity of pathways that control functions where RFPL4 is involved, leading to its functional inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, and by inhibiting MEK1/2, downstream signaling pathways, potentially involving RFPL4, can be inhibited. As a consequence, the functional activity of RFPL4 would be inhibited. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. By inhibiting PI3K activity, wortmannin can decrease the activation of pathways required for RFPL4 function, thereby functionally inhibiting RFPL4. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $150.00 $349.00 | 15 | |
ZM-447439 is an Aurora kinase inhibitor. If RFPL4 is involved in cell cycle regulation or mitotic processes regulated by Aurora kinases, then inhibition by ZM-447439 could lead to the functional inhibition of RFPL4. | ||||||